Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atacicept - Vera Therapeutics

Next Previous
Drug Profile

Atacicept - Vera Therapeutics

Alternative Names: Anti-Blys/anti-APRIL fusion protein - Vera Therapeutics; BLyS/APRIL-heterotrimers - Vera Therapeutics; TACI-Ig; VT-001

Latest Information Update: 17 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer EMD Serono; Merck Serono; Vera Therapeutics; ZymoGenetics
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration IgA nephropathy
  • Phase III Lupus nephritis
  • Phase II/III Systemic lupus erythematosus
  • Phase II Focal segmental glomerulosclerosis; Lipoid nephrosis; Membranous glomerulonephritis; Nephrotic syndrome
  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 08 Nov 2025 Preregistration for IgA nephropathy in USA (SC)
  • 06 Nov 2025 Vera Therapeutics anticipates Biologics License Application (BLA) submission of atacicept in IgA nephropathy (SC) in the US in Q4 2025
  • 06 Nov 2025 The US FDA assigns PDUFA action date in 2026 for atacicept for IgA nephropathy (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top